Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-center, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of AB-218 for Treating Adult Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumors

NCT05814536 is registered in ClinicalTrials.gov with AnHeart Therapeutics Inc. as lead sponsor.

NCT NCT05814536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05814536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-center, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of AB-218 for Treating Adult Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumors
Lead sponsor
AnHeart Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 6, 2023
Completion date
August 15, 2024
Enrollment
9 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma with idh1 mutation, solid tumors with idh1 mutation